Denmark Speeds Up  

Drug Development


Denmark organizes executive roundtable at Bio 2013 Conference in Chicago to present best practice R&D case studies by Novo Nordisk, AbbVie and Eli Lilly.

The increasing global demand for higher quality and more efficient healthcare at lower costs will benefit patients, payers, and providers. An essential part of the roadmap to better healthcare is shortening the timeframe for development of new treatments by using the right infrastructure to bring new drugs faster to the market and to patients’ bedsides.

For many years, Denmark has been actively working to guarantee the future of its pharma/biotech industries, with a long history of drug development and a strong science base. Denmark is among the top countries in the world producing biomedical research per capita.

This is reflected in the next generation of drug companies as well as in large companies such as Novo Nordisk and US companies AbbVie and Eli Lilly. These companies have worked to ensure the industry’s future through partnering and R&D activities in Denmark.

Bio 2013: Roundtable with Novo Nordisk, AbbVie and Eli Lilly

During the Bio conference this April in Chicago, Invest in Denmark is organizing an executive roundtable on R&D in Denmark on April 23 for major US biopharma companies. The roundtable will be moderated by professor Jens Mikkelsen from the University of Copenhagen and includes VP of Strategy from Novo Nordisk Finn Benned Hansen and Medical Director from AbbVie Pierre Quartarolo.

Professor Jens Mikkelsen: "Denmark is among the leaders in biomedical research. This is due to excellent universities and hospitals, robust funding, including success within the EU system and a strong biomedical industry, and last, but not least, the positive attitude towards biotech and health research from the public and private sectors."

New Danish Biobank

Last year, Denmark launched its National Biobank with more than 15 million biological specimens, offering unsurpassed opportunities for R&D:

Denmark also has the world’s oldest cancer registry, allowing foreign companies to accelerate R&D by establishing an entity in Denmark.

Several major US life science companies already have their eyes on Denmark:

  •       Agilent acquired cancer diagnostics company Dako last year
  •       Abbott bought a compound from Danish company Action Pharma
  •       Pfizer Consumer Healthcare acquired Ferrosan in 2011

For more information, interview opportunities and registration, please contact Investment Manager Mr. Jens Birk,; +1 9174971300.

Next step

Explore business cases


Tine Hartmann Nielsen

Tine Hartmann Nielsen

+45 3392 1350


Jens Birk

Jens Birk

+1 (917) 497 1300

Please contact me

How can we help you?

New Report

Life Science in Denmark

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×